BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
To prevent mortality and to reduce clinical signs and lesions of infectious bursal disease. To reduce mortality, clinical signs and lesions of Marek’s disease.
The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Our vision is a future where earlier detection and individualized treatment will stop vision loss in its tracks, protecting and preserving eyesight, and way of life.